Int. J. Mol. Sci. 2013, 14(3), 5170-5181; doi:10.3390/ijms14035170
Article

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma

1,2,* email, 1,2email, 1email, 1email, 3email, 2email, 4email and 1,2email
Received: 7 February 2013; in revised form: 20 February 2013 / Accepted: 25 February 2013 / Published: 4 March 2013
(This article belongs to the Section Molecular Pathology)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Accumulation of molecular alterations, including EGFR overexpression and mutations in KRAS and BRAF, contribute to colorectal carcinogenesis. Since intestinal-type adenocarcinoma (ITAC) of the nasal cavity and paranasal sinus has morphologic and phenotypic features that are usually indistinguishable from colorectal cancer (CRC), it is likely that both tumor types share equivalent genetic alterations. Data from a series of 43 patients treated surgically for ITAC in Montpellier, France between November 1998 and December 2012 were collected. Tumors were characterized for mutations in KRAS and BRAF as well as EGFR overexpression. Kaplan-Meier survival curves were constructed using overall survival as the primary end points. Patient survival was analyzed using the hazards ratio. Twenty seven tumors (63%) showed EGFR positivity and 30% exhibited a high expression level (+2/+3). KRAS mutations were detected in 43% of cases. BRAF mutations were identified in 3.6% of specimens. Patients with age superior to 60 years, metastatic status, and KRAS mutations had significant overall survival values (p = 0.026, p = 0.001 and p = 0.03, respectively). Our results indicate that KRAS mutations and EGFR expression are frequent in ITAC and that KRAS mutations predict good patient prognosis in ITAC. Finally, EGFR directed molecular treatments could be investigated in a subset of patients affected by ITAC.
Keywords: ITAC; KRAS; BRAF; EGFR expression; prognosis marker
PDF Full-text Download PDF Full-Text [741 KB, uploaded 19 June 2014 04:44 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Szablewski, V.; Solassol, J.; Poizat, F.; Larrieux, M.; Crampette, L.; Mange, A.; Bascoul-Mollevi, C.; Costes, V. EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. Int. J. Mol. Sci. 2013, 14, 5170-5181.

AMA Style

Szablewski V, Solassol J, Poizat F, Larrieux M, Crampette L, Mange A, Bascoul-Mollevi C, Costes V. EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma. International Journal of Molecular Sciences. 2013; 14(3):5170-5181.

Chicago/Turabian Style

Szablewski, Vanessa; Solassol, Jérôme; Poizat, Flora; Larrieux, Marion; Crampette, Louis; Mange, Alain; Bascoul-Mollevi, Caroline; Costes, Valérie. 2013. "EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma." Int. J. Mol. Sci. 14, no. 3: 5170-5181.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert